Journal List > Korean J Gastroenterol > v.71(1) > 1007736

Lee: Endoscopic Treatment for Pancreatic Cystic Lesions

Abstract

The decision of the appropriate treatment for pancreatic cystic lesions (PCLs) is becoming increasingly important as the number of incidentally found PCLs increases. A range of modalities have been attempted because there has been an increasing demand for minimally invasive treatment for PCLs due to the large burden of a surgical resection. Endoscopic treatment using endoscopic ultrasonography (EUS), a representative of minimally invasive therapy, can be categorized into two types: ablation therapy by the injection of drugs and topical thermal coagulative therapy through the high topical energy. A number of studies reported the feasibility and efficacy of these treatments; the most common is EUS-guided ablation for PCLS with ethanol alone or in combination with anticancer drugs. Although ablation therapies with drug injection have proven safety and feasibility, there is no consensus regarding the actual treatment effects and indications of these modalities. EUS-guided radiofrequency ablation was recently attempted as a representative method of local thermal coagulation, but further studies will be needed because of the lack of evidence of its feasibility and safety. In addition, a range of treatments for malignant tumors rather than PCLs have been attempted, such as EUS-guided photodynamic therapy, EUS-guided neodymium-doped yttrium aluminum garnet laser, and high-intensity focused ultrasound, based on the data from animal experiments. Through further study, endoscopic treatment is expected to become established as a useful treatment modality for PCLs.

Figures and Tables

Table 1

Suggested Management of Suspected BD-IPMN Modified from the Fukuoka Guideline Revised in 20172

kjg-71-10-i001

BD-IPMN, branch duct type intraductal papillary mucinous neoplasm; CA 19-9, carbohydrate antigen 19-9; CT, computed tomography; MRI, magnetic resonance imaging; EUS, endoscopic ultrasonography.

aConsider surgery in young, fit patients with need for prolonged surveillance; bStrongly consider surgery in young, fit patients.

Table 2

Literature Review of Studies of EUS-guided Ablation in PCLs

kjg-71-10-i002

EUS, endoscopic ultrasonography; PCLs, pancreatic cystic lesions; CR, complete remission; E, ethanol; G, gemcitabine; P, paclitaxel; NA, not applicable; AE, adverse events; SAE, severe adverse events; MCN, mucinous cystic neoplasm; IPMN, intraductal papillary mucinous neoplasm.

Notes

Financial support None.

Conflict of interest None.

References

1. Stark A, Donahue TR, Reber HA, Hines OJ. Pancreatic cyst disease: a review. JAMA. 2016; 315:1882–1893.
2. Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17:738–753.
crossref
3. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012; 12:183–197.
crossref
4. Vege SS, Ziring B, Jain R, Moayyedi P. Clinical Guidelines Committee. American Gastroenterology Association. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148:819–822. quize12-13.
crossref
5. Choi JH, Seo DW, Song TJ, et al. Long-term outcomes after endoscopic ultrasound-guided ablation of pancreatic cysts. Endoscopy. 2017; 49:866–873.
crossref
6. Park JK, Song BJ, Ryu JK, et al. Clinical outcomes of endoscopic ultrasonography-guided pancreatic cyst ablation. Pancreas. 2016; 45:889–894.
crossref
7. Moyer MT, Sharzehi S, Mathew A, et al. The safety and efficacy of an alcohol-free pancreatic cyst ablation protocol. Gastroenterology. 2017; 153:1295–1303.
crossref
8. Gómez V, Takahashi N, Levy MJ, et al. EUS-guided ethanol lavage does not reliably ablate pancreatic cystic neoplasms (with video). Gastrointest Endosc. 2016; 83:914–920.
crossref
9. Gelczer RK, Charboneau JW, Hussain S, Brown DL. Complications of percutaneous ethanol ablation. J Ultrasound Med. 1998; 17:531–533.
crossref
10. Gan SI, Thompson CC, Lauwers GY, Bounds BC, Brugge WR. Ethanol lavage of pancreatic cystic lesions: initial pilot study. Gastrointest Endosc. 2005; 61:746–752.
crossref
11. DeWitt J, McGreevy K, Schmidt CM, Brugge WR. EUS-guided ethanol versus saline solution lavage for pancreatic cysts: a randomized, double-blind study. Gastrointest Endosc. 2009; 70:710–723.
crossref
12. DiMaio CJ, DeWitt JM, Brugge WR. Ablation of pancreatic cystic lesions: the use of multiple endoscopic ultrasound-guided ethanol lavage sessions. Pancreas. 2011; 40:664–668.
13. Caillol F, Poincloux L, Bories E, et al. Ethanol lavage of 14 mucinous cysts of the pancreas: a retrospective study in two tertiary centers. Endosc Ultrasound. 2012; 1:48–52.
crossref
14. Kandula M, Moole H, Cashman M, Volmar FH, Bechtold ML, Puli SR. Success of endoscopic ultrasound-guided ethanol ablation of pancreatic cysts: a meta-analysis and systematic review. Indian J Gastroenterol. 2015; 34:193–199.
crossref
15. Oh HC, Seo DW, Lee TY, et al. New treatment for cystic tumors of the pancreas: EUS-guided ethanol lavage with paclitaxel injection. Gastrointest Endosc. 2008; 67:636–642.
crossref
16. Oh HC, Seo DW, Song TJ, et al. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts. Gastroenterology. 2011; 140:172–179.
crossref
17. DeWitt JM, Al-Haddad M, Sherman S, et al. Alterations in cyst fluid genetics following endoscopic ultrasound-guided pancreatic cyst ablation with ethanol and paclitaxel. Endoscopy. 2014; 46:457–464.
crossref
18. Moyer MT, Dye CE, Sharzehi S, et al. Is alcohol required for effective pancreatic cyst ablation? The prospective randomized CHARM trial pilot study. Endosc Int Open. 2016; 4:E603–E607.
crossref
19. Paiella S, Salvia R, Ramera M, et al. Local ablative strategies for ductal pancreatic cancer (radiofrequency ablation, irreversible electroporation): a review. Gastroenterol Res Pract. 2016; 2016:4508376.
crossref
20. Signoretti M, Valente R, Repici A, Delle Fave G, Capurso G, Carrara S. Endoscopy-guided ablation of pancreatic lesions: technical possibilities and clinical outlook. World J Gastrointest Endosc. 2017; 9:41–54.
crossref
21. Pai M, Habib N, Senturk H, et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg. 2015; 7:52–59.
crossref
22. Barthet M, Giovannini M, Lesavre N, et al. UEG week 2017 oral presentations-OP 315: EUS-guided radiofrequency ablation (RFA) for pancreatic neuroendocrine tumor (NET) and pre-malignant intraductal pancreatic mucinous tumor (IPMN): first results of prospective multicenter study. United European Gastroenterol J. 2017; 5:Suppl. A1–A160.
23. Song TJ, Seo DW, Lakhtakia S, et al. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc. 2016; 83:440–443.
crossref
24. Choi JH, Lee SH, Kim JS, et al. PBS24-comparison of natural course versus EUS-guided ethanol ablation for pancreatic cystic lesions. In : Proceedings of the 66th congress of the Korean Society of Gastrointestinal Endoscopy; Seoul, Korea: 2016.
25. Choi JH, Lee SH, Choi YH, et al. PB2-safety and adverse events of EUS-guided ethanol ablation for pancreatic cystic lesions: a single center experience with 188 patients. In : Proceedings of the 1st Korea Digestive Disease Week (KDDW); Seoul, Korea: 2017.
26. Arcidiacono PG, Carrara S, Reni M, et al. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc. 2012; 76:1142–1151.
crossref
27. Chan HH, Nishioka NS, Mino M, et al. EUS-guided photodynamic therapy of the pancreas: a pilot study. Gastrointest Endosc. 2004; 59:95–99.
crossref
28. Yusuf TE, Matthes K, Brugge WR. EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video). Gastrointest Endosc. 2008; 67:957–961.
crossref
29. Choi JH, Oh D, Lee JH, et al. Initial human experience of endoscopic ultrasound-guided photodynamic therapy with a novel photosensitizer and a flexible laser-light catheter. Endoscopy. 2015; 47:1035–1038.
crossref
30. Di Matteo F, Martino M, Rea R, et al. US-guided application of Nd:YAG laser in porcine pancreatic tissue: an ex vivo study and numerical simulation. Gastrointest Endosc. 2013; 78:750–755.
31. Di Matteo F, Martino M, Rea R, et al. EUS-guided Nd:YAG laser ablation of normal pancreatic tissue: a pilot study in a pig model. Gastrointest Endosc. 2010; 72:358–363.
crossref
32. Sofuni A, Moriyasu F, Sano T, et al. Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer. World J Gastroenterol. 2014; 20:9570–9577.
crossref
33. Sung HY, Jung SE, Cho SH, et al. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas. 2011; 40:1080–1086.
crossref
34. Suzuki R, Irisawa A, Bhutani MS. Endoscopic ultrasound-guided oncologic therapy for pancreatic cancer. Diagn Ther Endosc. 2013; 2013:157581.
crossref
TOOLS
Similar articles